Discover
OVID
Ovid Therapeutics Inc.
2.41
1 x 2.07
3 x 2.43
bid
ask
+
0.10
4.56%
1 @ 04:00 PM
2.46 +0.05 (2.07%)
| Ytd | 47.85% | |
| 1y | 298.08% |
2.29
day range
2.44
0.47
52 week range
3.10
| Open | 2.30 | Prev Close | 2.31 | Low | 2.29 | High | 2.44 | Mkt Cap | 317.84M |
| Vol | 1.78M | Avg Vol | 2.38M | EPS | -0.29 | P/E | -8.31 | Forward P/E | -2.44 |
| Beta | 0.18 | Short Ratio | 3.05 | Inst. Own | 56.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 2.51 | 200-d Avg | 2.01 | 1yr Est | 3.26 |
| Income Statement | |||
| Operating Expenses | 17.85M | ||
| Research and Development Expense | 11.18M | ||
| Selling, General and Administrative Expense | 6.67M | ||
| Operating Income | -17.85M | ||
| Net Income | -16.99M | ||
| Net Income Common Stock | -16.99M | ||
| Net Income Common Stock (USD) | -16.99M | ||
| Consolidated Income | -16.99M | ||
| Earnings per Basic Share | -0.12 | ||
| Earnings per Basic Share (USD) | -0.12 | ||
| Earnings per Diluted Share | -0.12 | ||
| Earning Before Interest & Taxes (EBIT) | -16.99M | ||
| Earning Before Interest & Taxes (USD) | -16.99M | ||
| Weighted Average Shares | 136.17M | ||
| Weighted Average Shares Diluted | 136.17M | ||
| Balance Sheet | |||
| Cash and Equivalents | 96.00M | ||
| Cash and Equivalents (USD) | 96.00M | ||
| Investments | 113.50M | ||
| Investments Current | 61.46M | ||
| Investments Non-Current | 52.04M | ||
| Current Assets | 160.15M | ||
| Property, Plant & Equipment Net | 11.52M | ||
| Total Assets | 225.63M | ||
| Debt Current | 1.46M | ||
| Total Debt | 13.07M | ||
| Current Liabilities | 15.75M | ||
| Debt Non-Current | 11.61M | ||
| Total Liabilities | 27.36M | ||
| Accumulated Retained Earnings (Deficit) | -338.70M | ||
| Accumulated Other Comprehensive Income | -422.00K | ||
| Shareholders Equity | 198.27M | ||
| Shareholders Equity (USD) | 198.27M | ||
| Assets Non-Current | 65.48M | ||
| Total Debt (USD) | 13.07M | ||
| Liabilities Non-Current | 11.61M | ||
| Trade and Non-Trade Payables | 8.88M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 347.00K | ||
| Net Cash Flow from Financing | 88.98M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 80.91M | ||
| Issuance (Purchase) of Equity Shares | 88.98M | ||
| Net Cash Flow from Investing | 5.95M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 5.95M | ||
| Net Cash Flow from Operations | -13.90M | ||
| Effect of Exchange Rate Changes on Cash | -122.00K | ||
| Share Based Compensation | 1.05M | ||